Loading
Children's cancers are treated with combinations, but companies study new drugs in children one at a time. Approvals should require the combination study children actually need.
The US RACE for Children Act requires paediatric evaluation of molecularly targeted adult cancer drugs, but permits single-agent studies that rarely lead to use, because paediatric standards of care are multi-drug backbones. Requiring the paediatric plan to include a combination with the relevant backbone, designed with cooperative groups, would produce actionable evidence.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets.